Inactive Instrument

Lidds AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Lidds AB

Financials

Sales 2021 3.55M 326K 27.16M Sales 2022 1.89M 173K 14.43M Capitalization 58.92M 5.4M 450M
Net income 2021 -37M -3.39M -283M Net income 2022 -36M -3.3M -275M EV / Sales 2021 81.8 x
Net cash position 2021 34M 3.12M 260M Net cash position 2022 1.26M 116K 9.66M EV / Sales 2022 30.5 x
P/E ratio 2021
-8.2 x
P/E ratio 2022
-1.58 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 63.36%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 53 01/21/01
Corporate Officer/Principal - 01/22/01
Corporate Officer/Principal 61 01/04/01
Members of the board TitleAgeSince
Director/Board Member 62 09/01
Director/Board Member 62 09/01
Director/Board Member 49 01/19/01
More insiders
Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Company’s portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.
Calendar
More about the company